Combination Of PAXIL Tablet And Benzodiazepines

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive episodes who have received Benzodiazepines for at least 4 weeks, and changes in the symptoms of depression will be evaluated by use of the rate and extent of decrease in Hamilton Rating Scale for Depression (HAM-D).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Paroxetine

Criteria

Inclusion criteria:

• Patients with depression or depressive episodes who are diagnosed to have major depressive disorders according to the DSM-IV criteria.

• Patients with 14 or higher points in total scores for Items No.1 - 17 on HAM-D.

• Patients who have continuously received Benzodiazepine anxiolytics.

Exclusion criteria:

• Patients with a strong suicide tendency.